IL1B and Alzheimer disease: One attribute is the steroid-sparing benefit of IDC + IDL [90,91], which aligns with its anti-inflammatory properties observed in previous studies using tissue culture models of AD [89] where co-treatment of IDC + IDL downregulated inflammatory mediators (IL1B, ITGA5) as well as neurogenic pruritic mediators (TRP1, TRPV3, TSLP).